Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q3 FY2024 Earnings Presentation
22 slides from Healthcare Global Enterprises's earnings presentation, Feb 8, 2024
Slide 1: Exchange intimation letter for investor presentation
February 08, 2024 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam,
Slide 2: Healthcare Global Enterprises Limited Investor Presentation
HEALTHCARE GLOBAL ENTERPRISES LIMITED I NV ESTOR P R ESENTATI ON February 2024
Slide 3: Safe Harbor
SAFE HARBOR This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Q3 & 9MFY24 Financial & Operational Highlights
Q3 & 9MFY24 FINANCIAL & SUBASENI LENKA, CANCER WINNER OPERATIONAL HIGHLIGHTS I am eternally thankful to Dr. Panda and other specialists at HCG Panda Cancer Hospital, as the specialists were able to treat my condition the right way, the first time 3 www. h c g o n c o l o g y. c o m
Slide 5: Clinical Highlights & Recognitions
Clinical Highlights & Recognitions Latest Publications ❖ Shaurya Verma : Lymph node level ratio: Are we relying too much on numbers? ❖ Raj Nagarkar : Lingual Artery as the Recipient Vessel of Choice in Patients Requiring a Second or Third Free Flap in Recurrent Oral Cancers and Vessel-Depleted Neck:
Slide 6: Our CSR Initiatives – World Cancer Day 2024
Our CSR Initiatives – World Cancer Day 2024 Campaign Power Of Good Wishes - A Collective Beacon of Hope Goal Create a repository of positive wishes from strangers for cancer warriors. Raise awareness about cancer and the HCG brand by engaging the general population. Empower individuals to become can
Slide 7: Financial Highlights Q3 FY24
Financial Highlights Q3 FY24 REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers +11% +11% -2% 4,699 4,535 167 164 4,247 4,080 Q3FY23 Q3FY24 Q3FY23 Q3FY24 Q3FY23 Q3FY24 ADJUSTED EBITDA PROFIT AFTER TAX PROFIT AFTER TAX ADJUSTED EBITDA* MARGIN* (Pre-IND AS) (Post-IND AS) +7% - 63
Slide 8: Financial Highlights 9M FY24
Financial Highlights 9M FY24 REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers +13% +14% 0% 14,175 13,671 505 504 12,526 12,021 9M FY23 9M FY24 9M FY23 9M FY24 9M FY23 9M FY24 ADJUSTED EBITDA PROFIT AFTER TAX PROFIT AFTER TAX ADJUSTED EBITDA* MARGIN* (Pre-IND AS) (Post-IND AS)
Slide 9: Improved Performance Leading to Profitability
Improved Performance Leading to Profitability 1.6x 4079 4200 4247 4422 4,607 4,870 4,699 3231 3520 3581 3646 Revenue 2981 (INR mn) Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 2.0x EBITDA (Excl. ESOP) 740 760 773 778 765 864 826 632 636 652 (INR mn) 396 488 Q4'21 Q1'22 Q2'
Slide 10: Growth Across HCG Centers
Growth Across HCG Centers Matured Centers Emerging Centers ~1.3x g r o w t h i n l a s t 9 q u a r t e r s ~1.5x g r o w t h i n l a s t 9 q u a r t e r s REVENUE +8% +19% 3,173 3,315 3,477 3,323 1,090 1,129 1,216 1,211 2,979 3,090 3,065 945 1,015 2,628 2,663 826 929 785 Q3FY22 Q4FY22 Q1FY23 Q2FY23
Slide 11: Strong Operating Metrics with Significant Capacity Headroom
Strong Operating Metrics with Significant Capacity Headroom Key Driver Metric Indicator % Revenue Q3’23 Q3’24 9 M’ 2 3 9 M’ 2 4 12% 274 306 21% Lead indicator of Volume Growth; key OPD Footfall (‘000) operating metric tracked by HCG; has 18%* 91 110 correlation to OPD Footfalls 9% 6% 100 109 Key ind
Slide 12: HCG – Q3FY24 Operational Metrics
HCG – Q3FY24 Operational Metrics # MATURED CENTERS EMERGING CENTERS MATURED CENTERS TOTAL AOR (%) AOR (%) A O R ^* ( % ) ROCE (%) 59.8% 59.3% 61.0% 18.5% 65.7% in Q3FY23 63.2% in Q3FY23 71.9% in Q3FY23 18.9% in Q3FY23 590 bps 390 bps 1,090 bps 40 bps ROCE pre-corporate a l l o ca t i o n s s ta n d
Slide 13: HCG – Cluster Wise Revenue Break Up
HCG – Cluster Wise Revenue Break Up C LU ST E R Q3FY24 Q3FY23 Y-o-Y 9MFY24 9MFY23 Y-o-Y K A R N ATA K A * 1,422.9 1,395.8 2% 4,500.5 4,193.3 7% G U J A R AT 1,174.8 1,025.3 15% 3,526.2 3,079.0 15% MAHARASHTRA 727.8 615.7 18% 2,099.5 1,780.6 18% EAST INDIA 532.6 419.7 27% 1,554.3 1,208.6 29% ANDHRA P
Slide 14: Milann – Implementing Strategic Initiatives
Milann – Implementing Strategic Initiatives BENGALURU (5 Centers) Growth Growth Particulars Q3FY24 Q3FY23 9MFY24 9MFY23 Y-o-Y Y-o-Y M S Ramaiah Nagar New 1,011 1,215 -16.8% 3,488 3,979 -12.3% Registrations Shivananda Indiranagar IVF Cycles 381 464 -17.9% 1,260 1,475 -14.6% Whitefield Sarjapur JP Nag
Slide 15: Capital Expenditure & Net Debt
Capital Expenditure & Net Debt CAPITAL EXPENDITURE (Rs. Mn.) NET DEBT (Rs. Mn.) NET DEBT 31 st Dec 2023 30 th Sept 2023 HCG CENTERS 9MFY24 FY23 Bank Debt ( 1) 4,615 3,798 Vendor Finance ( 2) 318 320 Matured Centers 1,100 1,094 Other Debt 38 36 Emerging Centers 79 163 Less: Cash & Cash Equivalents (
Slide 16: Q3 & 9MFY24 Consolidated Profit & Loss Account
Q3 & 9MFY24 Consolidated Profit & Loss Account Profit and Loss (in Rs. Mn.) Q3 FY24 Q3 FY23 Y-o-Y Q2 FY24 Q-o-Q 9M FY24 9M FY23 Y-o-Y Revenues from Operations 4,689.5 4,239.1 4,859.6 14,146.2 12,504.3 Income from Govt. Grant 9.2 7.7 9.8 28.7 23.0 Total Revenue from Operations 4,698.7 4,246.8 10.6% 4
Slide 17: Historical Financial Highlights
HISTORICAL FINANCIAL SHANKAR, CANCER WINNER HIGHLIGHTS The days I was at HCG, I felt like I was sleeping at home. They never stop caring for you. The doctors and nurses are always finding ways to make this difficult journey as comfortable as possible 16 www. h c g o n c o l o g y. c o m
Slide 18: Historical Profit & Loss Account
Historical Profit & Loss Account Profit and Loss (in Rs. Mn.) FY23 FY22 FY21 FY20 FY19 CAGR Revenues from Operations 16,914 13,948 10,092 10,923 9,760 Income from Govt. Grant 30 30 43 33 27 Total Revenue from Operations 16,944 13,978 10,134 10,956 9,787 15% Costs of Goods Sold 4,241 3,549 3,632 3,64
Slide 19: Historical Balance Sheet
Historical Balance Sheet Balance Sheet - Equity & Liabilities (in Rs. Mn.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 1,391 1,390 1,254 887 879 Other Equity 7,214 7,313 5,718 2,926 3,933 Equity Attributable To Equity Holders Of The Company 8,605 8,703 6,972 3,813 4,811 Non-Controlling I
Slide 20: Historical Balance Sheet
Historical Balance Sheet Balance Sheet - Assets (in Rs. Mn.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, Plant And Equipment 9,718 9,315 8,531 9,271 8,026 Capital Work in Progress 182 217 300 461 1,440 Rights-of-use Assets 3,813 4,045 4,114 5,776 0 Goodwill 1,812 1,813 963 1,093
Slide 21: Historical Cash Flow Statement
Historical Cash Flow Statement Cash Flow Statement (in Rs. Mn) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Net Profit Before Tax 449 878 -2,287 -1,193 -334 Adjustments For: Non - Cash Items / Other Investment Or Financial 2,753 1,666 3,619 2,988 2,463 Items Operating Profit Before Working Capital Changes 3,2
Slide 22: Thank You
THANK YOU Company: HealthCare Global Enterprises Limited Investor Relation Advisors: Strategic Growth Advisors CIN: L15200KA1998PLC023489 CIN: U74140MH2010PTC204285 For updates and specific queries, please visit Mr. Sagar Shroff / Mr. Ayush Haria www.hcgoncology.com sagar.shroff@sgapl.net / ayush.ha
HealthCare Global Enterprises — Q3 FY2024 Earnings Presentation on 6ix